On March 28th, we hosted a live webinar featuring an expert panel of physicians from Boston Children's Hospital, Texas Children's Hospital, and the University of Minnesota. The panel discussed special considerations for caring for pediatric patients with C. difficile including diagnosis and treatment with FMT.
Key takeaways and an FAQ is shared below.
OpenBiome will continue distributing UMN-manufactured FMT for patients suffering from recurrent C. difficile (rCDI). To access this material, a new registration form must be completed. This applies to all sites, even if you have an existing OpenBiome agreement.
Emergency Access Restriction Lifted: OpenBiome’s partnership with UMN has enabled us to lift the ‘emergency only’ shipping policy that was in place since August 2021. If you have patients that are eligible for an FMT to treat rCDI, you may place an order without applying for emergency access.
Plans to Expand On-hand Inventory: As we have ramped up operations, we expanded access by allowing sites to maintain on-hand inventory. Partner sites can now maintain an inventory of up to 5 units of FMT.